Document:

Exhibit
10.8

 

This
Business Advisory Board Services Agreement (the “Agreement”), dated June 23, 2017, is entered into between Zander
Therapeutics, Inc., a Nevada corporation (“the Company), and Brian Devine, an individual with a principal place of residence
California(“Candidate”).

WHEREAS,
the Company desires to retain the services of Candidate for the benefit of the Company and its stockholders; and

WHEREAS,
Candidate desires to serve as Chairman of the Company’s Business Advisory Board for the period of time and subject to
the terms and conditions set forth herein;

NOW,
THEREFORE, for consideration and as set forth herein, the parties hereto agree as follows:

		1.	Board
                                         Duties.  Candidate agrees to provide services to the Company as Chairman
                                         of the Company’s Business Advisory Board. Candidate shall, for so long as he remains
                                         a member of the Business Advisory Board, meet with the Company upon written request,
                                         at dates and times mutually agreeable to Candidate and the Company, to discuss any matter
                                         involving the Company or its Subsidiaries

		2.	Other
                                         Duties. Candidate will utilize his best efforts to:

		(a)	Identify
                                         and introduce to the Company persons not previously known to the Company to serve as
                                         members of the Company’s Business Advisory Board (“Advisory Candidates”).

		(b)	Identify
                                         and introduce to the Company potential purchasers of the Company’s securities,
                                         such purchasers not previously known to the Company (“Buyers”). Candidate
                                         shall solely identify and introduce Buyers to the Company and shall not, among other
                                         things, participate in any negotiations between a Buyer and the Company, assist in the
                                         structure of any offer or sale of the Company’s securities (“Transaction”),
                                         provide assistance to any party in completing a purchase agreement, subscription agreement
                                         or other documentation related to a Transaction or handle the funds or securities involved
                                         in any Transaction.

		3.	Term.
                                         The Term of this Agreement shall commence on June 23, 2017 and shall expire on June
                                         23, 2020. The term of this Agreement may be extended by mutual agreement.

		4.	Independent
                                         Contractor. The Parties are independent contractors. Nothing in this Agreement shall
                                         be deemed to constitute a partnership or joint venture between the Parties or constitute
                                         any Party to be the agent of the other Party for any purpose.

		5.	No
                                         obligation: This Agreement does not constitute an obligation on the part of the Company
                                         to:

		(a)	Enter
                                         into any Transaction with any Buyer

		(b)	Accept
                                         as a member of the Business Advisory Board any Advisory Candidate

 

    	 	1	 

     

    

		6.	Mutual
                                         Non-Disparagement. During the term of this Agreement and for a period of twelve
                                         months thereafter, Candidate and the Company mutually agree to forbear from making,
                                         causing to be made, publishing, ratifying or endorsing any and all disparaging remarks,
                                         derogatory statements or comments made to any party with respect to either of them or
                                         their respective officers, directors, and employees. The parties agree and acknowledge
                                         that this Section 6 is a material term of this Agreement.

 

		7.	Non
                                         Disclosure.

(a)
All information, whether in oral, written, graphic, electronic or other form, disclosed by the Company to the Candidate shall
be deemed to be “Proprietary Information.” In particular, Proprietary Information includes, without limitation, any
trade secrets, confidential information, ideas, inventions or research and development information; matters of a technical nature,
including technology; notes, products, know-how, engineering or other data (including test data and data files); specifications,
processes, techniques, formulae or work-in-process; manufacturing, planning or marketing procedures, clinical data and regulatory
strategies or information; accounting, financial or pricing procedures or information, budgets or projections, or personnel or
salary structure/compensation information; information regarding suppliers, clients, customers, employees, contractors, investors
or investigators of the Company, information which has been designated in writing as confidential by the Company; programs, procedures
(including operating procedures), processes, methods, guidelines, policies, proposals or contracts; computer software, data bases
or programming; and any other information which, if divulged to a third party, could have an adverse impact on the Company, or
on any third party to which it owes a confidentiality obligation. In addition, “Proprietary Information” includes
any of the foregoing relating to the past, present or future operations, organization, projects, finances, business interests,
methodology or affairs of any third party to which the Company owes a duty of confidentiality including, without limitation, the
mere fact that the Company is or may be working with or for any client.

(b)
The obligations of confidentiality shall not apply to any Proprietary Information that was known by the Candidate at the time
of disclosure to it by such Company, or that is independently developed or discovered by the Candidate after disclosure by such
Company, without the aid, application or use of any item of such Company’s Proprietary Information, as evidenced by written
records; now, or subsequently becomes, through no act or failure to act on the part of the Candidate, generally known or available;
is disclosed to the Candidate by a third party authorized to disclose it; or is required by law or by court or administrative
order to be disclosed; provided, that the Candidate shall have first given prompt notice to such Company of such required disclosure.

 

    	 	2	 

     

    

 

	 	(c)	Candidate
    shall exercise due care to prevent the unauthorized use or disclosure of the Company’s Proprietary Information, and
    shall not, without the Company’s prior written consent, disclose or otherwise make available, directly or indirectly,
    any item of the Company’s Proprietary Information to any person or entity other than those employees, independent contractors
    or agents of the Candidate (collectively, “Representatives”), to the extent such Representatives reasonably need
    to know the same in order to evaluate such Proprietary Information, to participate in the business relationship between the
    parties, or to make decisions or render advice in connection therewith. Candidate shall advise its Representatives who have
    access to the Company’s Proprietary Information of the confidential and proprietary nature thereof, and agrees that
    such Representatives shall be bound by terms of confidentiality and restrictions on use with respect thereto that are at least
    as restrictive as the terms of this Agreement.

 

	 	(d)	Candidate
    shall exercise due care to prevent the unauthorized use or disclosure of the Company’s Proprietary Information, and
    shall not, without the Company’s prior written consent, disclose or otherwise make available, directly or indirectly,
    any item of the Company’s Proprietary Information to any person or entity other than those employees, independent contractors
    or agents of the Candidate (collectively, “Representatives”), to the extent such Representatives reasonably need
    to know the same in order to participate in any business relationship between the parties, or to make decisions or render
    advice in connection therewith. Candidate shall advise its Representatives who have access to the Company’s Proprietary
    Information of the confidential and proprietary nature thereof, and agrees that such Representatives shall be bound by terms
    of confidentiality and restrictions on use with respect thereto that are at least as restrictive as the terms of this Agreement.

 

	 	(e)	Candidate
    shall use the Company’s Proprietary Information solely for the purposes of performing his duties pursuant to this Agreement
    and shall not make any other use of the Company’s Proprietary Information without the Company’s specific written
    authorization.

 

	 	(f)	All
    Proprietary Information of the Company (including all copies thereof) shall be and at all times remain the property of such
    Company, and all non-oral Proprietary Information of the Company which is then in the Candidate’s possession or control
    shall be destroyed or returned to the Company promptly upon its request at any time, and in any event, no later than 60 days
    following any expiration or termination of this Agreement. 

 

	 	(g)	Nothing
    in this Agreement shall be construed, by implication or otherwise, as a grant of any right or license to trademarks, inventions,
    copyrights or patents, as a grant of a license to either Candidate to use any of the Company’s Proprietary Information
    except as expressly set forth herein.

 

	 	(h)	The
    provisions of Section 7 of this Agreement shall survive until such time as all Confidential Information disclosed hereafter
    becomes publically known and made generally available through no action or inaction of Candidate. 

 

		8.	Compensation.

    	 	3	 

     

    

		(a)	For
                                         performance of duties pursuant to Section 1 of this Agreement, Candidate will receive,
                                         no later than ten days from the execution of this Agreement 500,000 of the common shares
                                         of the Company.

		(b)	For
                                         performance of duties pursuant to Section 2 of this Agreement, Candidate will receive:

		(i)	In
                                         the event that an Advisory Candidate identified and introduced by you to the Company
                                         serves as a member of the Business Advisory Board of the Company, the Candidate shall
                                         receive, ten business days subsequent to the completion of 12 months service by the Advisory
                                         Candidate as a member of the Business Advisory Board of the Company, a 5% referral fee
                                         of shares issued to the Candidate paid in Common Shares of the Company.

		9.	Restricted
                                         Securities Acknowledgement

 

Candidate
acknowledges that any securities issued pursuant to this Agreement that shall not be registered pursuant to the Securities Act
of 1933 shall constitute “restricted securities” as that term is defined in Rule 144 promulgated under the Securities
Act of 1933, and shall contain the following restrictive legend:

“THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.”

	 	10.	Representations and Warranties of Company.

a)
Company is a corporation duly organized, validly existing and in good standing under the laws of the state its incorporation and
has the requisite corporate power and authority to enter into and perform its obligations under this Agreement without the consent,
approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

 

    	 	4	 

     

    

		(c)	The
                                         execution, delivery and performance of this Agreement by Company does not and shall not
                                         constitute Company’s breach of any statute or regulation or ordinance of any governmental
                                         authority, and shall not conflict with or result in a breach of or default under any
                                         of the terms, conditions, or provisions of any order, writ, injunction, decree, contract,
                                         agreement, or instrument to which the Company is a party, or by which Company is or may
                                         be bound.

		11.	Representation
                                         and Warranties of the Candidate.

 

(a)
Candidate has the requisite power and authority to enter into and perform his obligations under this Agreement without the consent,
approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

(b)
The execution, delivery and performance of this Agreement by Candidate does not and shall not constitute Candidate’s breach
of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of
or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument
to which the Candidate is a party, or by which Candidate is or may be bound.

12.
Execution

This
Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same Agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood
that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile signature page were an original thereof.

13.
Entire Agreement

This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties. 

14.
Severability

    	 	5	 

     

    

If
any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefore, and upon so agreeing, shall incorporate
such substitute provision in this Agreement

15.
Governing Law, Venue, Waiver Of Jury Trial

All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such
proceeding. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

	COMPANY	 	CANDIDATE
	By:/s/
    David R. Koos	 	By:
    /s/ Brian Devine
	David
                                         R. Koos, Chairman and CEO

        Date:
        June 20, 2017
	 	Brian
    Devine
	 	 	 
	 	 	Date:
    June 21, 2017Exhibit 10.9

 

Agreement made on March 20, 2017 (“Execution
Date”) by and between Linda Black (“Consultant”), a natural person whose address is ___________and Entest BioMedical
Inc.

(“Company”), a Nevada corporation
whose address is 4700 Spring Street, St 304, La Mesa, California 91942. Consultant and Company may be referred to individually
as “Party” and collectively as “Parties”.

 

 

It is agreed as follows:

 

1. SCOPE OF SERVICES

Consultant shall advise client on various nominal
matters regarding veterinary biotechnology for the Company's wholly owned subsidiary Zander Therapeutics Inc. "Nominal"
is defined as periodic conversations in which Consultant is asked for a referral to an appropriate researcher on a specific topic
or input on research model the company is developing. In the event Consultant is requested to provide research services, such services
will be negotiated separately between Consultant and the Company.

 

2. TERM

The Term of this Agreement shall commence on
March 20, 2017 and shall expire on March 19, 2018. The term of this Agreement may be extended by mutual agreement.

 

3. INDEPENDENT CONTRACTOR

The Parties are independent contractors. Nothing
in this Agreement shall be deemed to constitute a partnership or joint venture between the Parties or constitute any Party to be
the agent of the other Party for any purpose.

 

4. NON-DISCLOSURE

(a) All information, whether in oral, written,
graphic, electronic or other form, disclosed by the Company to the Consultant shall be deemed to be “Proprietary Information.”
In particular, Proprietary Information includes, without limitation, any trade secrets, confidential information, ideas, inventions
or research and development information; matters of a technical nature, including technology; notes, products, knowhow, engineering
or other data (including test data and data files); specifications, processes, techniques, formulae or work-in-process; manufacturing,
planning or marketing procedures, clinical data and regulatory strategies or information; accounting, financial or pricing procedures
or information, budgets or projections, or personnel or salary structure/compensation information; information regarding suppliers,
clients, customers, employees, contractors, investors or investigators of the Company, information which has been designated in
writing as confidential by the Company; programs, procedures (including operating procedures), processes, methods, guidelines,
policies, proposals or contracts; computer software, data bases or programming; and any other information which, if divulged to
a third party, could have an adverse impact on the Company, or on any third party to which it owes a confidentiality obligation.
In addition, “Proprietary Information” includes any of the foregoing relating to the past, present or future operations,
organization, projects, finances, business interests, methodology or affairs of any third party to which the Company owes a duty
of confidentiality including, without limitation, the mere fact that the Company is or may be working with or for any client.

 

(b) The obligations of confidentiality shall
not apply to any Proprietary Information that was known by the Consultant at the time of disclosure to it by such Company, or that
is independently developed or discovered by the Consultant after disclosure by such Company, without the aid, application or use
of any item of such Company’s Proprietary Information, as evidenced by written records; now, or subsequently becomes, through
no act or failure to act on the part of the Consultant, generally known or available; is disclosed to the Consultant by a third
party authorized to disclose it; or is required by law or by court or administrative order to be disclosed; provided, that the
Consultant shall have first

given prompt notice to such Company of such
required disclosure.

 

(c) Consultant shall exercise due care to prevent
the unauthorized use or disclosure of the Company’s Proprietary Information, and shall not, without the Company’s prior
written consent, disclose or otherwise make available, directly or indirectly, any item of the Company’s Proprietary Information
to any person or entity other than those employees, independent contractors or agents of the Consultant (collectively, “Representatives”),
to the extent such Representatives reasonably need to know the same in order to evaluate such Proprietary Information, to participate
in the business relationship between the parties, or to make decisions or render advice in connection therewith. Consultant shall
advise its Representatives who have access to the Company’s Proprietary Information of the

    	 	1	 

     

    

confidential and proprietary nature thereof,
and agrees that such Representatives shall be bound by terms of confidentiality and restrictions on use with respect thereto that
are at least as restrictive as the terms of this Agreement.

 

(d) Consultant shall exercise due care to prevent
the unauthorized use or disclosure of the Company’s Proprietary Information, and shall not, without the Company’s prior
written consent, disclose or otherwise make available, directly or indirectly, any item of the Company’s Proprietary Information
to any person or entity other than those employees, independent contractors or agents of the

Consultant (collectively, “Representatives”),
to the extent such Representatives reasonably need to know the same in order to participate in any business relationship between
the parties, or to make decisions or render advice in connection therewith. Consultant shall advise its Representatives who have
access to the Company’s Proprietary Information of the confidential and proprietary nature thereof, and agrees that such
Representatives shall be bound by terms of confidentiality and restrictions on use with respect thereto that are at least as restrictive
as the terms of this Agreement.

 

(e) Consultant shall use the Company’s
Proprietary Information solely for the purposes of performing his duties pursuant to this Agreement and shall not make any other
use of the Company’s Proprietary Information without the Company’s specific written authorization.

 

(f) All Proprietary Information of the Company
(including all copies thereof) shall be and at all times remain the property of such Company, and all non-oral Proprietary Information
of the Company which is then in the Consultant’s possession or control shall be destroyed or returned to the Company promptly
upon its request at any time, and in any event, no later than 60 days following any expiration or termination of this Agreement.

 

(g) Nothing in this Agreement shall be construed,
by implication or otherwise, as a grant of any right or license to trademarks, inventions, copyrights or patents, as a grant of
a license to either Consultant to use any of the Company’s Proprietary Information except as expressly set forth herein.

 

(h) The provisions of Section 4 of this Agreement
shall survive until such time as all Confidential Information disclosed hereafter becomes publically known and made generally available
through no action or inaction of Consultant.

 

5. CONSIDERATION

As consideration of the performance of services
pursuant to this Agreement, Consultant shall receive:

 

(1) Within 15 business days of the execution
date of this Agreement Consultant shall be issued 100,000 shares of the Series B Preferred Stock of the Company (“Compensation
Shares”).

 

(2) Within 30 business days subsequent to the
effective date of a Registration Statement filed under the Securities Act of 1933, as amended, registering common shares of Zander
Therapeutics, Inc. (“Zander Registration Statement”) Consultant shall have the right to exchange up to the total number
of the Compensation Shares issued to the Consultant pursuant to the terms and conditions of this Agreement for an equivalent number
of the common shares of Zander Therapeutic, Inc. six months after Zander Therapeutics Inc. clears a registration statement. This
right shall be withdrawn in the event of any breach of the terms and conditions of this Agreement by the Consultant.

 

(3) Consultant acknowledges that nothing in
this Agreement shall obligate either of the Company or Zander Therapeutics Inc. to register the common shares of Zander Therapeutics,
Inc. under the Securities Act of 1933, as amended.

 

(4) Consultant acknowledges that, in the event
that a Zander Registration Statement is filed with the United States Securities and Exchange Commission (“SEC”), no
assurance is given that the Zander Registration Statement will be declared effective by the SEC.

 

(5) Consultant acknowledges that any securities
issued pursuant to this Agreement that are not registered pursuant to the Securities Act of 1933 shall constitute “restricted
securities” as that term is defined in Rule 144 promulgated under the Securities Act of 1933, and shall contain the following
restrictive legend:

    	 	2	 

     

    

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED,
PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE
STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE
COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM
THE ACT OR SUCH LAWS.

 

6. REPRESENTATIONS AND WARRANTIES OF COMPANY

(a) Company is a corporation duly organized,
validly existing and in good standing under the laws of the state its incorporation and has the requisite corporate power and authority
to enter into and perform its obligations under this Agreement without the consent, approval or authorization of, or obligation
to notify, any person, entity or governmental agency which consent has not been obtained.

 

(b) The execution, delivery and performance
of this Agreement by Company does not and shall not constitute Company’s breach of any statute or regulation or ordinance
of any governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions,
or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Company is a party, or by
which Company is or may be bound.

 

7. REPRESENTATIONS AND WARRANTIES OF CONSULTANT

(a) Consultant has the requisite power and
authority to enter into and perform his obligations under this Agreement without the consent, approval or authorization of, or
obligation to notify, any person, entity or governmental agency which consent has not been obtained.

 

(b) The execution, delivery and performance
of this Agreement by Consultant does not and shall not constitute Consultant’s breach of any statute or regulation or ordinance
of any governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions,
or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Consultant is a party, or
by which Company is or may be bound.

 

8. NON-DISPARAGEMENT

Consultant agrees that Consultant shall not,
during the term of this Agreement, disparage the Company, the Company’s products, the Company’s employees, or members
of the Company’s board of directors. For purposes of this Agreement the term “disparage” shall mean any negative
comment, written or oral, about the Company, the Company’s products, the Company’s employees, or members of the Company’s
board of directors. . Nothing set forth in this Agreement shall prohibit or limit in any way a Party’s right to accurately
and honestly respond as required or to cooperate with any valid government, court or regulatory order or request. The provisions
of Section 8 of this Agreement shall survive until that date which is three years subsequent to the end of the Term of this Agreement.

 

9. WORK PRODUCT

Consultant agrees that the Company is the sole
and exclusive owner of all intellectual property, including copyrights, trademarks, patents, inventions, work product and know-how,
which may result from any work performed by the Consultant pursuant to this Agreement. Consultant agrees that Consultant shall,
upon request of the Company, execute, acknowledge, deliver and file any and all documents necessary or useful to vest in the Company
all of Consultant’s right, title and interest in and to all intellectual property, including copyrights, trademarks, patents,
inventions, work product and know-how, which may result from any work performed by the Consultant pursuant to this Agreement. The
term "Inventions" means all original works of authorship, developments, concepts, improvements or trade secrets, whether
or not patentable under law, that Consultant may individually or jointly conceive or develop or reduce to practice, or cause to
be conceived or developed or reduced to practice which may result from any work performed by the Consultant pursuant to this Agreement

 

10. SPECIFIC PERFORMANCE

Any breach of this Agreement may result in
irreparable damage to Company for which Company will not have an adequate remedy at law. Accordingly, in addition to any other
remedies and damages available, Consultant

    	 	3	 

     

    

acknowledges and agrees that Company may immediately
seek enforcement of this Agreement by means of specific performance or injunction, without any requirement to post a bond or other
security.

 

11. EXECUTION

This Agreement may be executed in two or more
counterparts, all of which when taken together shall be considered one and the same Agreement and shall become effective when counterparts
have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart.
In the event that any signature is delivered by facsimile transmission, such signature shall create a valid and binding obligation
of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile signature
page were an original thereof.

 

12. ENTIRE AGREEMENT

This Agreement constitutes a final written
expression of all the terms of the Agreement between the parties regarding the subject matter hereof, are a complete and exclusive
statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings, and representations between
the parties.

 

13. SEVERABILITY

If any provision of this Agreement is held
to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement
shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision
that is a reasonable substitute therefore, and upon so agreeing, shall incorporate such substitute provision in this Agreement

 

14. GOVERNING LAW, VENUE, WAIVER OF JURY TRIAL

All questions concerning the construction,
validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the
internal laws of the State of California, without regard to the principles of conflicts of law thereof. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in California for the adjudication of any dispute
hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein and hereby irrevocably waives,
and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of
any such court, that such suit, action or proceeding is improper or inconvenient venue for such proceeding. If either party shall
commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or proceeding
shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.

 

IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be duly executed by their

respective authorized signatories as of the
date first indicated above.

 

CONSULTANT

 

By:/s/Linda Black

 

Date: March 21, 2017

 

COMPANY

 

By: /s/Harry Lander, Ph.D. By:

____________________

Its: President and CSO

Date: March 17, 2017

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]